GNMX - アエヴィ・ジェノミック・メディシン (Aevi Genomic Medicine Inc.)

GNMXのニュース

   Aevi Genomic Medicine (NASDAQ:GNMX) Shares Down 7.7%  2019/11/13 05:20:14 Modern Readers
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $0.12 and last traded at $0.12, 1,020,600 shares traded hands during mid-day trading. A decline of 40% from the average session volume of 1,697,638 shares. The stock had previously closed at $0.13. Separately, ValuEngine […]
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Aevi Genomic's AEVI-001 flunks mid-stage ADHD study  2019/01/02 21:46:01 Seeking Alpha
   Aevi Genomic Medicine (NASDAQ:GNMX) Shares Down 7.7%  2019/11/13 05:20:14 Modern Readers
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $0.12 and last traded at $0.12, 1,020,600 shares traded hands during mid-day trading. A decline of 40% from the average session volume of 1,697,638 shares. The stock had previously closed at $0.13. Separately, ValuEngine […]
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Aevi Genomic's AEVI-001 flunks mid-stage ADHD study  2019/01/02 21:46:01 Seeking Alpha
   Aevi Genomic Medicine (NASDAQ:GNMX) Shares Down 7.7%  2019/11/13 05:20:14 Modern Readers
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $0.12 and last traded at $0.12, 1,020,600 shares traded hands during mid-day trading. A decline of 40% from the average session volume of 1,697,638 shares. The stock had previously closed at $0.13. Separately, ValuEngine […]
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Aevi Genomic's AEVI-001 flunks mid-stage ADHD study  2019/01/02 21:46:01 Seeking Alpha

calendar